ABVC BioPharma AI Stock Analysis
Want to see ABVC full AI Analyst Report?
ABVC BioPharma (ABVC) AI Stock Analysis
ABVC BioPharma
(NASDAQ:ABVC)
The overall score is very low, driven primarily by a catastrophic financial performance with zero revenue and ongoing cash burn. This is compounded by a weak technical trend, a negative P/E ratio, and recent corporate events that confirm the company is resorting to highly dilutive, distressed financing to stay afloat. The company's survival is entirely dependent on its ability to repeatedly raise external capital.
ABVC BioPharma (ABVC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $25.99M
- Dividend Yield
- ―
- Average Volume (3M)
- 86.76K
- Price to Earnings (P/E)
- -4.5
- Beta (1Y)
- 2.12
- Revenue Growth
- -100.00%
- EPS Growth
- 39.04%
- Country
- US
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ABVC BioPharma Business Overview & Revenue Model
Company Description
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key cand...
How the Company Makes Money
ABVC’s revenue model is primarily based on monetizing its drug-development pipeline rather than selling established commercial products. The company seeks to generate income through (1) out-licensing and collaboration agreements, where third parties...
ABVC BioPharma Financial Statement Overview
Summary
Financial health is critically weak. Revenue has collapsed to zero, net losses persist, and the company is burning approximately $3 million in cash annually with no operational income. The recent balance sheet improvement is entirely dependent on dilutive financing and is unsustainable without a fundamental business turnaround.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -795.95K | 0 | 509.59K | 152.43K | 969.78K | 355.80K |
| Gross Profit | -795.95K | 0 | 508.83K | -149.61K | 683.37K | 350.71K |
| EBITDA | -7.05M | -7.43M | -4.34M | -6.33M | -15.20M | -10.97M |
| Net Income | -4.71M | -7.91M | -4.90M | -7.79M | -16.42M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 20.30M | 21.06M | 7.54M | 7.78M | 10.93M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 66.45K | 745.83K | 928.55K | 796.09K | 1.47M | 5.94M |
| Total Debt | 2.51M | 3.47M | 3.20M | 2.77M | 3.41M | 3.34M |
| Total Liabilities | 8.55M | 7.76M | 6.82M | 6.53M | 6.34M | 4.83M |
| Stockholders Equity | 13.05M | 11.11M | 1.23M | 1.55M | 4.45M | 8.84M |
Cash Flow | ||||||
| Free Cash Flow | -2.75M | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
| Operating Cash Flow | -3.00M | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Investing Cash Flow | 652.44K | -1.21M | 0 | -360.19K | -1.72M | -805.97K |
| Financing Cash Flow | 1.44M | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
ABVC BioPharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.02, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.20 is Neutral, neither overbought nor oversold. The STOCH value of 34.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVC.
ABVC BioPharma Risk Analysis
ABVC BioPharma disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskABVC BioPharma Peers Comparison
Overall Rating
CAMP46Neutral
HYFT45Neutral
INKT45Neutral
JSPR44Neutral
CRVO42Neutral- ABVC38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CAMP | 46Neutral | $263.57M | -1.97 | -261.83% | ― | 39.93% | 16.95% |
| HYFT | 45Neutral | $49.00M | -3.79 | -144.31% | ― | -26.89% | 56.50% |
| INKT | 45Neutral | $52.17M | -4.47 | 9999.00% | ― | ― | 25.94% |
| JSPR | 44Neutral | $16.37M | -0.29 | -618.87% | ― | ― | 73.74% |
| CRVO | 42Neutral | $26.78M | -0.66 | -164.95% | ― | -99.86% | 4.48% |
| ABVC | 38Underperform | $26.76M | -4.50 | -41.67% | ― | -100.00% | 39.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ABVC | ABVC BioPharma, Inc. | 0.91 | -1.99 | -68.62% | |
| CRVO | Cervomed Inc. | 1.69 | -6.52 | -79.42% | |
| HYFT | Mindwalk Holdings Corp. | 0.99 | -0.73 | -42.44% | |
| JSPR | Jasper Therapeutics, Inc. | 13.68 | -40.02 | -74.52% | |
| INKT | Mink Therapeutics, Inc. | 9.34 | -2.66 | -22.17% | |
| CAMP | CAMP4 Therapeutics Corporation | 3.80 | -0.19 | -4.76% |
ABVC BioPharma Corporate Events
ABVC BioPharma Closes $4.11 Million Convertible Note Financing
NegativeOn October 30, 2026, ABVC closed a private placement of senior convertible promissory notes with $4.11 million in principal and approximately $3.39 million in purchase proceeds. The notes carried a 17.5% original issue discount, matured on June 30, 2...
ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction
NeutralOn August 21, 2026, ABVC BioPharma completed the legal and structural separation of its subsidiary, BioKey (Cayman), Inc., distributing roughly 15% of BioKey Cayman’s ordinary shares to ABVC common stockholders as a pro rata dividend. Shareholders re...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026